A Phase II Study Evaluating the Toxicity and Efficacy of Single Agent Lenalidomide (Revlimid) in Chemotherapy-Naive Androgen-Independent Prostate Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2014
At a glance
- Drugs Lenalidomide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 03 Aug 2010 Planned number of patients changed from 25 to 35 as reported by ClinicalTrials.gov.
- 03 Aug 2010 Planned end date changed from 1 Feb 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.